Anbogen Therapeutics, Inc.
7784 · TPEx
Public Market Listing
7784TPEx
Live quotes, historical charts, and market capitalization for Anbogen Therapeutics, Inc. are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | EGFR / HER2 exon 20 mutationsSmall molecule | Non-Small Cell Lung Cancer |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
November 2026 (1)
Est. primary completion 2026-11 · NCT05532696 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.